| abstract |
Disclosed is the use of a population of isolated adherent placental cells in the manufacture of a medicament for the treatment of a bone defect in a human individual, wherein the bone defect is an osteolytic lesion associated with cancer, a bone fracture, or a spine in need of fusion, wherein said placental stem cells are present in an amount sufficient to treat said bone defect; wherein said population is CD105+, CD200+, CD10+, and CD34-, and wherein said medicament is implantable or injectable. The stem cells are not human totipotent cells. |